Date: 31-Aug-2019

Half of all safety warnings issued to drug manufacturers in India and China

he number of regulatory breaches at drug manufacturing sites in India and China raises concerns about the fragility of the global supply chain, says a report by The Pharmaceutical Journal According to a report by The Pharmaceutical Journal, The majority of warnings from European and US drug regulators are to drug manufacturing sites in India and China, raising concerns about the fragility of the global supply chain